NASDAQ · RPHM
Reneo Pharmaceuticals, Inc.
Healthcare · Biotechnology
$18.20
Up+$16.47 (+952.02%)
Updated Sep 16, 2026, 12:49 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 60.84M
- P/E ratio
- 73.07
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 437.52K
- Avg. volume
- 16.86K
Price performance
RPHM price history
1M range · 0 trading sessions · Daily adjusted prices
RPHM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest RPHM news
The latest Smart Investors Daily articles mentioning RPHM.
Stock researchCompany · Overview
RPHM research
Overview
Company profile and research snapshot.
Company profile
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2024 | HC Wainwright & Co. | Neutral | — |
| Dec 15, 2023 | HC Wainwright & Co. | Neutral | — |
| Dec 15, 2023 | Jefferies | Hold | — |
| Dec 15, 2023 | Leerink Partners | Market Perform | — |
| Nov 15, 2023 | William Blair | Outperform | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.
